Abstract:Summary Background Although the outbreak of Coronavirus disease 2019 (COVID-19) has caused over 2200 deaths in China, there was no study about death yet. We aimed to describe the clinical characteristics of non-survivors with COVID-19. Methods For this retrospective, single-center study, we included 36 non-survivors with COVID-19 in the Fifth Hospital of Wuhan. Cases were confirmed by real-time RT-PCR between Jan 21 and Feb 10, 2020 according to the recommended protocol. The epidemiological, demographic, clinical, laboratory, radiological and treatment data were collected and analyzed. Outcomes were followed up until Feb 14, 2020. This study was approved by the ethics commissions of the Fifth Hospital of Wuhan, with a waiver of informed consent due to a public health outbreak investigation. Findings We included 36 patients who died from COVID-19. The mean age of the patients was 69.22 years (SD 9.64, range 50-90). 25(69.44%) patients were males, and 11 (30.56%) female. 26 (72.22%) patients had chronic diseases, mainly including hypertension, cardiovascular disease and diabetes. Patients had common clinical symptoms of fever (34 [94.44%] patients), cough (28 [77.78%] patients), shortness of breath (21 [58.33%] patients), and fatigue (17 [47.22%] patient). Chest computed tomographic scans showed that 31 (96.88%) patients had bilateral pneumonia. Lymphopenia (lymphocyte count, 0.67□×□109/L [SD, 0.33]) occurred in 24 patients (70.59%), decreased albumin (30.18, [SD, 4.76]) in 25 patients (80.65%), elevated D-dimer (8.64 [IQR, 2.39-20]) in 27 patients (100%), and elevated lactate dehydrogenase (502.5 U/L [IQR, 410-629]) in 26 patients (100%). Nearly all of the patients have elevated CRP (106.3 mg/L [IQR, 60.83-225.3]), PCT (0.61 ng/ml [IQR, 0.16-2.10]) and IL-6 (100.6 pg/ml [IQR, 51.51-919.5]). Most patients received antiviral therapy and antibiotic therapy, and more than half of patients received glucocorticoid therapy (25 [69.44%]). All the patients had acute respiratory distress syndrome (ARDS). The median time from onset to ARDS was 11 days. One (2.78%) patient presented with acute renal injury. The median time from onset to death was 17 days. Interpretation Lots of patients died from COVID-19 till now. The median survival time of these non-survivors from onset to death was about 2 weeks. Most patients were older males with comorbidities. They finally progressed to ARDS. The median time from onset to ARDS was 11 days. Gradually decreased lymphocytes and increased inflammation biomarkers were common, and need to be monitored in the routine treatment. Funding There is no any funder involved in this study. Research in context Evidence before this study SARS-CoV-2 has been spreading in China as well as in other countries. We searched PubMed for articles published up to Feb 15, 2020. Serveral articles that describe the epidemiological and clinical characteristics of general COVID-19 patients. However, special reports about dead cases of COVID-19 were limited but warranted, considering the large amount of confirmed cases, which is still increasing Added value of this study We retrospectively analysed specific clinical information of 36 non-survivors infected with SARS-CoV-2 in this single-centered study. Most patients were older males with comorbidities. Gradually decreased lymphocytes and increased inflammation biomarkers were found in these patients. They finally progressed to ARDS. The median time from onset to ARDS was 11 days. The mean survival time in our cohort of COVID-19 non-survivors was about 2 weeks. Implications of all the available evidence Lots of patients died from COVID-19 till now. The median survival time of these non-survivors from onset to death was about 2 weeks. Most patients were older males with comorbidities. They finally progressed to ARDS. Early detection and intervention of patients are especially important which can delay the development from mild to severe cases.

Clinical characteristics and risk of death of 194 patients with severe covid-19

Risk Factors for Mortality of Coronavirus Disease 2019 (COVID-19) Patients During the Early Outbreak of COVID-19: a Systematic Review and Meta-Analysis

Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID‐19 patients

Risk factors associated with fatal outcomes of novel coronavirus infection pneumonia (COVID-19): A systematic review and meta-analysis

Clinical Characteristics and Immune Responses of 137 Deceased Patients With COVID-19: A Retrospective Study

Clinical characteristics and risk factors of fatal patients with COVID-19: a retrospective cohort study in Wuhan, China

Clinical characteristics and a decision tree model to predict death outcome in severe COVID-19 patients

Case–control study on risk factors for in-hospital mortality in patients with severe COVID-19

Disease Progression Patterns And Risk Factors Associated With Mortality In Deceased Patients With Covid-19 In Hubei Province, China

Risk factors for mortality of coronavirus disease-2019 (COVID-19) patients in two centers of Hubei province, China: A retrospective analysis

The characteristics of laboratory tests at admission and the risk factors for adverse clinical outcomes of severe and critical COVID-19 patients

Clinical Risk Factors for Mortality of Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis

Risk Factors for Fatal Outcome in Patients with Severe COVID-19: an Analysis of 107 Cases in Wuhan

Clinical Predictors of COVID-19 Disease Progression and Death: Analysis of 214 Hospitalised Patients from Wuhan, China.

Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study

The characteristics and outcomes of 681 severe cases with COVID-19 in China

Clinical Features and Risk Factors of Severely and Critically Ill Patients with COVID-19.

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Filter screening of antibody Fab fragments secreted from individual bacterial colonies: specific detection of antigen binding with a two-membrane system.

Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China

Early Identification of Patients with Severe COVID-19 at Increased Risk of In-Hospital Death: a Multicenter Case-Control Study in Wuhan